News You Can Use

The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.

Targeted radioactive therapy for prostate cancer, new SBRT approaches, personalized radiation and more

Soared past 90% in VA system for low-risk disease, to 61% for favorable intermediate-risk disease

Alternative cancer clinics may market unvetted therapies and target vulnerable patients online.

A two drug combination may help stop aggressive prostate cancers that escape treatment by changing their cellular identity.

In this episode of Bench to Bedside and Beyond, we talk to a prostate cancer survivor and the medical director of Fred Hutch's cancer rehab about treatment's aftermath.